AbolerIS Pharma is a technology company.
AbolerIS Pharma is a technology company.
AbolerIS Pharma has raised $29.0M across 1 funding round.
AbolerIS Pharma has raised $29.0M in total across 1 funding round.
AbolerIS Pharma is a Belgian biopharmaceutical company developing first-in-class monoclonal antibodies to restore immune system balance in chronic autoimmune and inflammatory diseases.[1][2][4] Its lead program, ABO21009—an anti-CD45RC antibody—targets pathogenic T and B cells while preserving useful immune responses, addressing high unmet needs in conditions like rheumatoid arthritis; the company has advanced to clinical-stage, with the first cohort dosed in a Phase 1 study.[1][2] Backed by investors like Sound Bioventures, AbolerIS focuses on inducing immune tolerance for inflammatory, autoimmune, and degenerative diseases, serving patients who lack effective treatments.[2][4]
AbolerIS Pharma was founded by three renowned scientists: Dr. Carole Guillonneau, Dr. Ignacio Anegon, and Dr. François-Xavier Hubert, leveraging their expertise in immunology and autoimmune disease research.[4] The idea emerged from their work on therapeutic targets for pathological immune responses, with Guillonneau inventing 19 related patents and coordinating discovery projects.[4] Early traction included pre-clinical development of immunomodulators for transplant rejection, graft-versus-host disease, and autoimmunity, culminating in a Series A financing and progression to clinical trials, including the April 2025 announcement from Gosselies, Belgium, and Nantes, France.[1][2][4]
AbolerIS rides the autoimmunity treatment wave, where immune tolerance therapies address limitations of existing drugs that broadly suppress immunity, risking infections.[1][2][4] Timing aligns with rising autoimmune disease prevalence and biotech momentum in precision immunomodulation, bolstered by events like the 2025 EULAR Congress.[1] Market forces favor it through investor interest (e.g., Sound Bioventures) and regulatory progress, positioning AbolerIS to influence the ecosystem by pioneering CD45RC-targeting for rheumatoid arthritis and beyond, potentially expanding to transplants and neurodegeneration.[2][4]
AbolerIS Pharma's Phase 1 momentum with ABO21009 signals a potential game-changer in autoimmunity, with upcoming data readouts and congress presentations shaping validation.[1][2] Trends like personalized immunomodulation and AI-driven target discovery will accelerate its pipeline, possibly leading to partnerships or Phase 2 trials by 2026. Its influence could grow by filling gaps in immune-balancing therapies, evolving from clinical-stage contender to key player in restoring immune control for millions. This positions AbolerIS as a precise innovator in a chaotic disease landscape.[1][4]
AbolerIS Pharma has raised $29.0M in total across 1 funding round.
AbolerIS Pharma's investors include Caixa Capital.
AbolerIS Pharma has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series A in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $29.0M Series A | Caixa Capital |